Biomedical Engineering Reference
In-Depth Information
156. Einhorn TA, Lane JM, Burstein AH et al. The healing of segmental bone defects induced by
demineralized bone matrix. A radiographic and biomechanical study. J Bone Joint Surg Am 1984;
66(2):274-9.
157. Frost H. The biology of fracture healing part I. Clinical Orthopedics 1989; 248:283-293.
158. Frost H. The biology of fracture healing part II. Clin Orthop 1989; 248:293-309.
159. Chen Y. Orthopedic applications of gene therapy. J Orthop Sci 2001; 6(2):199-207.
160. Connolly JF, Guse R, Tiedeman J et al. Autologous marrow injection for delayed unions of the
tibia: A preliminary report. J Orthop Trauma 1989; 3(4):276-82.
161. Baltzer AW, Lattermann C, Whalen JD et al. Potential role of direct adenoviral gene transfer in
enhancing fracture repair. Clin Orthop 2000; (379 Suppl):S120-5.
162. Baltzer AW, Lattermann C, Whalen JD et al. Genetic enhancement of fracture repair: Healing of
an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther 2000;
7(9):734-9.
163. Boden SD, Zdeblick TA, Sandhu Hs et al. The use of rhBMP-2 in interbody fusion cages. Defini-
tive evidence of osteoinduction in humans: A preliminary report. Spine 2000; 25(3):376-81.
164. Cochran DL, Jones AA, Lilly LC et al. Evaluation of recombinant human bone morphogenetic
protein-2 in oral applications including the use of endosseous implants: 3-year results of a pilot
study in humans. J Periodontol 2000; 71(8):1241-57.
165. Wozney JM. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 1992;
32(2):160-7.
166. Reddi AH. Bone and cartilage differentiation. Curr Opin Genet Dev 1994; 4(5):737-44.
167. Lieberman JR, Daluiski A, Stevenson S et al. The effect of regional gene therapy with bone mor-
phogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in
rats. J Bone Joint Surg Am 1999; 81(7):905-17.
168. Bonadio J. Tissue engineering via local gene delivery. J Mol Med 2000; 78(6):303-11.
169. Riggs BL, Melton 3rd LJ. The worldwide problem of osteoporosis: Insights afforded by epidemiol-
ogy. Bone 1995; 17(5 Suppl):505S-511S.
170. Schneider EL, Guralnik JM. The aging of America. Impact on health care costs. Jama 1990;
263(17):2335-40.
171. Hock JM. Stemming bone loss by suppressing apoptosis. J Clin Invest 1999; 104(4):371-3.
172. Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorp-
tion on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 1992; 7(1):65-72.
173. Shen V, Dempster DW, Birchman R et al. Loss of cancellous bone mass and connectivity in
ovariectomized rats can be restored by combined treatment with parathyroid hormone and estra-
diol. J Clin Invest 1993; 91(6):2479-87.
174. Shen V, Dempster DW, Mellish RW et al. Effects of combined and separate intermittent admin-
istration of low-dose human parathyroid hormone fragment (1-34) and 17 beta-estradiol on bone
histomorphometry in ovariectomized rats with established osteopenia. Calcif Tissue Int 1992;
50(3):214-20.
175. Seeman ED, PD. Reconstructing the skeleton with intermittent parathyroid hormone. Trends in
Endocrinological Metabolism 2001; 12(7):281-283.
176. Morley PW, Willick JF, GE. Parathyroid hormone: An anabolic treatment for osteoporosis. Curr
Pharm Des 2001; 7(8):671-87.
177. Brommage R, Hotchkiss CE, Lees CJ et al. Daily treatment with human recombinant parathyroid
hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin
Endocrinol Metab 1999; 84(10):3757-63.
178. Tam CS, Heersche JN, Murray TM et al. Parathyroid hormone stimulates the bone apposition
rate independently of its resorptive action: Differential effects of intermittent and continuous ad-
ministration. Endocrinology 1982; 110(2):506-12.
179. Steinmann JC, Herkowitz HN. Pseudarthrosis of the spine. Clin Orthop 1992; (284):80-90.
180. Boden SD, Schimandle JH, Hutton WC. 1995 Volvo award in basic sciences. The use of an
osteoinductive growth factor for lumbar spinal fusion. Part II: Study of dose, carrier, and species.
Spine 1995; 20(24):2633-44.
181. Helm GA, Sheehan JM, Sheehan JP et al. Utilization of type I collagen gel, demineralized bone
matrix, and bone morphogenetic protein-2 to enhance autologous bone lumbar spinal fusion. J
Neurosurg 1997; 86(1):93-100.
182. Sandhu HS, Kanim LE, Toth JM et al. Experimental spinal fusion with recombinant human bone
morphogenetic protein-2 without decortication of osseous elements. Spine 1997; 22(11):1171-80.
183. Marden LJ, Hollinger JO, Chaudhari A et al. Recombinant human bone morphogenetic protein-2
is superior to demineralized bone matrix in repairing craniotomy defects in rats. J Biomed Mater
Res 1994; 28(10):1127-38.
Search WWH ::




Custom Search